TP53 and hepatocellular carcinoma: Genetic and molecular alterations, such as TP53 mutations, have been frequently identified in aggressive HCC cases and are connected to poor prognosis, while CTNNB1 (β-catenin) mutations are coupled with better outcomes but also resistance to immune checkpoint inhibitors [31].